Efimosfermin alfa for adults with liver impairment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional trial gives a single dose of efimosfermin alfa to adults who have chronic, stable hepatic impairment due to steatotic liver disease and classifies participants by Child-Pugh score (B or C). The main goals are to characterize pharmacokinetics and monitor safety and tolerability across different degrees of liver dysfunction and alcohol exposure. Eligible participants are adults 18–70 years with BMI 23–40 kg/m2 and documented cirrhosis; stability of hepatic function is required prior to dosing. Study visits occur at GSK investigational sites in the United States and include blood sampling and clinical safety assessments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Between 18 years and 70 years of age inclusive
* Body Mass Index (BMI) within the range 23-40 kilogram per square meter (kg/m\^2)
* Male or female participants
* Participant has liver cirrhosis with a grade of hepatic impairment that can be classified as a discrete Child-Pugh class. Participants must:

  * Have a clinical diagnosis of liver cirrhosis in the participant's medical history corroborated by previous liver biopsy, medical imaging or compatible biochemical profile, and
  * Be classed during Screening as one of the following Child-Pugh classes:

    * Child-Pugh B: Score 7-9 or
    * Child-Pugh C: Score 10-15
* Chronic (greater than \[\>\] 6 months) HI which is currently stable (no acute episodes of illness within the previous 1 month prior to Screening (Visit 1) due to deterioration in hepatic function). Participants must also remain stable throughout the Screening period. Assessment of the stability of the participant's hepatic function will be determined by the investigator.

Exclusion Criteria:

* History of extrahepatic disorders possibly related to etiology of cirrhosis.
* History of cryoglobulinemia.
* Participants with Grade 3 ascites or refractory ascites.
* Participants with refractory encephalopathy or significant central nervous system disease
* History of gastric or esophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated with medication and/or surgical procedures.
* Other primary causes of liver disease. Steatotic liver disease must be the primary cause of liver disease.
* Clinically significant abnormalities affecting physical health in medical history, or on physical examination, that could interfere with or for which treatment could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this study.
* Current, or history of known hepatocellular carcinoma (HCC).
* Participants with transjugular intrahepatic portosystemic shunt (TIPS) placement.
* Presence of hepatopulmonary or hepatorenal syndrome.
* Presence of primarily cholestatic liver diseases.
* Evidence of symptomatic or complicated cholecystitis.
* History of pancreatic injury, pancreatitis, or other pancreatic disease.
* History of liver transplantation, or active on the liver transplant waiting list.
* Participants with signs of active infection
* History of adrenal gland disease or using treatment that affects the hypothalamic-pituitary-adrenal axis.
* History of significant bone disease such as osteoporosis
* Psychosocial features that, in the opinion of the investigator, increase the likelihood of loss to follow-up.
* History or presence of drug abuse.
* Use of other investigational drugs at the time of screening, or within 5 half-lives or 30 days prior to study intervention, whichever was longer; or longer if required by local regulations
* Have previously taken efimosfermin alfa
* Participants with Alanine Aminotransferase (ALT) value \>3 times (x) upper limit of normal (ULN)
* Participants with Aspartate aminotransferase (AST) value \>=300 Units/Liter.
* Participants with estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology \[CKD-Epi\] 2021) \<45 milliliter/minute/1.73 square meter (mL/min/1.73m\^2).
* Average of triplicate QT interval corrected for heart rate using Fridericia formula (QTcF) \>480 milliseconds (msec) (for male and female participants) at Screening
* For participants in the MASH with alcohol category, significant risk of withdrawal symptoms.

Where it's running

• GSK Investigational Site
  Rialto, California, United States Recruiting
• GSK Investigational Site
  Miami Lakes, Florida, United States Recruiting
• GSK Investigational Site
  Tampa, Florida, United States Recruiting
• GSK Investigational Site
  Houston, Texas, United States Recruiting
• GSK Investigational Site
  San Antonio, Texas, United States Recruiting

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center
• Email: GSKClinicalSupportHD@gsk.com
• Phone: 877-379-3718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver

  We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07599241

• Lowering insulin to reduce liver fat production

  This study will try a short course of diazoxide to lower insulin and see if it reduces the liver's creation of new fat in adults with obesity, insulin resistance, and MASLD.

  Recruiting Phase 1 Columbia University · New York, New York · NCT07403604

• Efimosfermin alfa for adults with biopsy-confirmed F2 or F3 MASH

  This trial will test whether efimosfermin alfa can resolve steatohepatitis and improve liver-related outcomes in adults with biopsy-confirmed F2 or F3 MASH.

  Recruiting at 91 sites Phase 3 GlaxoSmithKline · Chandler, Arizona and 90 other locations · NCT07221227

• Efimosfermin alfa injections for adults with F2–F3 MASH

  This study tests whether efimosfermin alfa injections are safe and tolerable for adults (18–75) with known or suspected metabolic dysfunction-associated steatohepatitis (MASH) and F2–F3 fibrosis.

  Recruiting at 66 sites Phase 3 GlaxoSmithKline · Arcadia, California and 65 other locations · NCT07221188

• Mediterranean diet with or without aerobic exercise for women with familial Mediterranean fever and fatty liver

  This trial will test whether adding regular aerobic exercise to a Mediterranean diet helps women with familial Mediterranean fever who have non-alcoholic fatty liver disease.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07130318

• Cardiovascular health in children and young adults with chronic conditions

  This project will see if children and young adults (ages 6-25) with chronic health conditions show early signs of aging in large and small blood vessels using noninvasive imaging and clinical tests.

  Recruiting Semmelweis University · Budapest and 2 other locations · NCT07086989

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.